We are live on ! Find out more
CINC

CinCor Pharma, Inc. Common Stock
CINC

Delisted

CINC was delisted on the 23rd of February, 2023.

Back to rankings

0 hedge funds and large institutions have $0 invested in CinCor Pharma, Inc. Common Stock in 2023 Q1 according to their latest regulatory filings, with 0 funds opening new positions, 0 increasing their positions, 0 reducing their positions, and 102 closing their positions.

New
Increased
Maintained
Reduced
Closed

100% less funds holding

Funds holding: 102 → 0 (-102)

100% less funds holding in top 10

Funds holding in top 10: 4 → 0 (-4)

100% less capital invested

Capital invested by funds: $461M → $0 (-$461M)

100% less first-time investments, than exits

New positions opened: 0 | Existing positions closed: 102

Holders
–
Holders Change
-102
Holders Change %
-100%
% of All Funds
–
Holding in Top 10
–
Holding in Top 10 Change
-4
Holding in Top 10 Change %
-100%
% of All Funds
–
New
–
Increased
–
Reduced
–
Closed
102
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

No buyers this quarter

Top Sellers

Rank Fund Capital Flow
1
SI
Sofinnova Investments
California
-$74.6M
2
5VM
5AM Venture Management
California
-$60.7M
3
GA
General Atlantic
New York
-$51.7M
4
PA
Perceptive Advisors
New York
-$31.7M
5
Adage Capital Partners
Adage Capital Partners
Massachusetts
-$24.5M
Name Holding Trade Value Shares
Change 		Change in
Stake
Walleye Capital
76
Walleye Capital
New York
– -$137K -11,166 Closed
LCM
77
Landscape Capital Management
New Jersey
– -$133K -10,836 Closed
Deutsche Bank
78
Deutsche Bank
Germany
– -$132K -10,705 Closed
OQS
79
Occudo Quantitative Strategies
Florida
– -$125K -10,155 Closed
SG Americas Securities
80
SG Americas Securities
New York
– -$123K -10,015 Closed
CAC
81
Cowen and Company
New York
– -$89.6K -7,292 Closed
Legal & General Group
82
Legal & General Group
United Kingdom
– -$85K -6,919 Closed
Barclays
83
Barclays
United Kingdom
– -$82K -6,671 Closed
TRCT
84
Tower Research Capital (TRC)
New York
– -$71K -5,807 Closed
SIM
85
Sandia Investment Management
Massachusetts
– -$59K -4,800 Closed
Osaic Holdings
86
Osaic Holdings
Arizona
– -$57K -4,675 Closed
AB
87
Amalgamated Bank
New York
– -$38K -3,111 Closed
Royal Bank of Canada
88
Royal Bank of Canada
Ontario, Canada
– -$35K -2,906 Closed
SO
89
STRS Ohio
Ohio
– -$33K -2,700 Closed
PMEF
90
Point72 Middle East FZE
United Arab Emirates
– -$25.8K -2,103 Closed
MLICM
91
Metropolitan Life Insurance Company (MetLife)
New York
– -$20.2K -1,642 Closed
AIP
92
Ameritas Investment Partners
Nebraska
– -$45.3K -1,571 Closed
Group One Trading
93
Group One Trading
Illinois
– -$16.1K -1,312 Closed
Citigroup
94
Citigroup
New York
– -$14.1K -1,146 Closed
BC
95
Bartlett & Co
Ohio
– -$10K -800 Closed
BCWM
96
Bartlett & Co Wealth Management
Ohio
– -$9.83K -800 Closed
Macquarie Group
97
Macquarie Group
Australia
– -$7K -609 Closed
CUAMC
98
China Universal Asset Management Company
China
– -$5.46K -444 Closed
Daiwa Securities Group
99
Daiwa Securities Group
Japan
– -$2K -176 Closed
QT
100
Quantbot Technologies
New York
– -$1.06K -86 Closed
1 2 3
4

CINC Hedge Fund Activity: Q1 2023 in Review

0 of the 6,275 institutional investors tracked by Wall St. Rank reported a position in CinCor Pharma, Inc. Common Stock (CINC) for Q1 2023, worth a combined $0 — down 100% from $461M a quarter earlier.

Sellers outnumbered buyers: 102 funds closed out of CINC and 0 opened new positions — a net loss of 102 holders — while 0 trimmed existing stakes and 0 added.

The largest seller was Sofinnova Investments, exiting entirely with an estimated $74.6M sold.

  • 0 institutional investors held CinCor Pharma, Inc. Common Stock (CINC) as of Q1 2023, down from 102 in Q4 2022.
  • Funds reported $0 of CinCor Pharma, Inc. Common Stock stock for Q1 2023, down 100% quarter-over-quarter.
  • 0 funds opened new CinCor Pharma, Inc. Common Stock positions in Q1 2023 and 102 closed out, a net change of -102 holders.
  • The largest CinCor Pharma, Inc. Common Stock seller in Q1 2023 was Sofinnova Investments, an estimated $74.6M sold.

Based on aggregated 13F filings for Q1 2023.